INTAS PHARMACEUTICALS LTD. Vs. MACLEODS PHARMACEUTICALS LTD.

JUDGEMENT

(1.) IAS 6604/2016 (under Order 39, Rule 1 & 2 CPC)

(2.) By the main suit, the plaintiff has taken exception to the adoption of the mark "GABAMIN" or its variation "GABAMIN NT" by the defendant in relation to its pharmaceutical (medicinal) products claimed to have been introduced in the market initially in June 2006, its active ingredients being "Gabapentin" and "Mecobalamin (Methylcobalamin)". By the application (IA 6604/2016) under Order 39, Rule 1 and 2 CPC, the plaintiff prayed for ad interim relief.

(3.) Arguments were heard at length and with the assistance of the learned senior counsel on both sides, record has been perused.